Wednesday, January 29, 2014

Pete Seeger and Government Violation of the First Amendment

If you think that some of us are being overly upset about the recent revelations of illegal NSA spying, remember our recent history. One is HUAC.  For more than 30 years the US House had a "House UnAmerican Activities Committee" which by itself is pretty much a violation of the Constitution. Led by various Chairmen and members who did not understand or agree with the First Amendment (e.g. Richard Nixon in the late 1940s), it ruined a lot of lives and careers.  

In this case in 1955, Chairman Francis Walter (D-Pa) and HUAC were after Pete Seeger for singing at communist, labor, and civil rights events.  I just read the full transcript, which is wonderful and scary at the same time. This began 7 years of prosecution for Seeger, who was convicted of contempt of Congress for refusing to answer questions about where he sang.  In 1961 he was sentenced to 10 years in jail (ultimately overturned). He paid a heavy financial price.

He said a version of the following, over and over:

"I decline to discuss, under compulsion, where I have sung, and who has sung my songs, and who else has sung with me, and the people I have known. I love my country very dearly, and I greatly resent this implication that some of the places that I have sung and some of the people that I have known, and some of my opinions, whether they are religious or philosophical, or I might be a vegetarian, make me any less of an American. I will tell you about my songs, but I am not interested in telling you who wrote them, and I will tell you about my songs, and I am not interested in who listened to them."


A picture and the full transcript are at this link. 
http://www.slate.com/blogs/browbeat/2014/01/28/pete_seeger_huac_transcript_full_text_of_anti_communist_hearing_courtesy.html

Friday, January 24, 2014

The mobile information revolution in Africa

Most of you are not techno dweebs like me.  However, we all need to understand the information revolution that is going on in Africa because, for those of us who work there, it will touch everything we do in major ways.  It is the same story in India.  Here are some easily accessible articles, the first from today on CNN.  Bottom line: almost everyone has a cell phone or access to one; the information platform (smart handsets and powerful mobile networks) are happening and happening fast.  This enables things we could only dream about before, most importantly in giving ordinary people access to information and knowledge to improve their well being, from agricultural information, to job listings, to personal vitality. 

Story from CNN today on the mobile explosion in Africa


From last fall, the smart phone is coming fast in Africa.  18% of the market last fall and moving up (as their price falls), just as the capacity of the networks is improving fast. 


And a broad look from 2012 on the 7 ways the mobile phone is changing Africa.  All still true, except much more



Wednesday, January 22, 2014

Monsanto's latest: better veggies?

Imagine what these guys would do if consumers had a clear, easy way of measuring nourishment outcomes: in the food and in themselves. They would follow the demand and create nourishing food instead of high sugar corn. Nutritional content and outcome is not the metric today; but it is coming, along with consumer devices to measure those.  Read this highly informative article from Wired.

Monsanto’s gene chipper “maps the parts of a genome that might be associated with a given trait, even if that trait arises from multiple genes working in concert. Researchers identify and cross plants with traits they like and then run millions of samples from the hybrid—just bits of leaf, really—through a machine that can read more than 200,000 samples per week and map all the genes in a particular region of the plant’s chromosomes.

“They had more toys too. In 2006, Monsanto developed a machine called a seed chipper that quickly sorts and shaves off widely varying samples of soybean germplasm from seeds. The seed chipper lets researchers scan tiny genetic variations, just a single nucleotide, to figure out if they’ll result in plants with the traits they want—without having to take the time to let a seed grow into a plant. Monsanto computer models can actually predict inheritance patterns, meaning they can tell which desired traits will successfully be passed on. It’s breeding without breeding, plant sex in silico. In the real world, the odds of stacking 20 different characteristics into a single plant are one in 2 trillion. In nature, it can take a millennium. Monsanto can do it in just a few years. And this all happens without any genetic engineering. Nobody inserts a single gene into a single genome.”


http://www.wired.com/wiredscience/2014/01/new-monsanto-vegetables/

Tuesday, January 14, 2014

Door Step Vitality: the Antidote to the Failings of Sick Care

Taking advantage of the information revolution to deliver evidence-based integrated vitality programs


The primary mission of healthcare for disadvantaged populations to date has been to treat disease and reduce death. The primary mission of feeding programs has been to fill bellies. These are worthy, but limited, goals. Merely keeping a malnourished mother and her stunted infant alive consigns the baby to a life of hardship and failure. Instead, our objective should be vitality: the capacity to achieve the full human possibilities, the capacity to be a success as a changemaker. 

Vitality is physical strength and mental vigor. Vitality requires physical and mental health; sanitation and full nourishment; personal empowerment/education and care from skilled professionals; and nourishment of humans and communities and their environment.

Achieving vitality requires new leaders with radically different goals, approaches and systems. These must be explicitly designed to transform from sick care to vitality, from expert-centered to person-centered, from siloed services to holistic, and from facilities-based medicine to “door step health.” What are the “holistic person solutions” to deliver vitality? The essential elements include full nourishment, primary healthcare, behavioral healthcare, safe drinking water and sanitation, and detailed outcomes measurement using modern technology from the global information revolution. 

Give people knowledge and control by personal education/empowerment about these elements, with information in their hands. Build a community that nourishes around them. Lift them up before they get sick; you get less sickness, and you can manage chronic illness better.

“Door step health” means using mobile ICT and diagnostics to enable services in people’s homes, where they work, and at local wellness centers, while connecting them to typical medical care when needed. Experience with this model indicates that it broadens access to care; it creates better compliance and behavior-change; it addresses the shortage of doctors and nurses by empowering lay health workers with IT-based protocols, mobile diagnostics, and interactive patient education tools; we believe it will achieve better outcomes at far lower cost than Western-style, facilities-based care; and it captures more comprehensive information (enabling far richer and faster research, including big data analysis).

This model also addresses the growing global malnutrition crisis, visible in both the hundreds of millions of stunted children and the worldwide obesity epidemic among adults. In addition, new scientific evidence shows that a seriously malnourished mother will give birth to a child with an altered profile of activated genes and far higher numbers of fat cells—and a lifelong propensity toward obesity, diabetes, and heart disease. Still other evidence shows the key role that insufficient or inappropriate nutrition plays in triggering the onset of chronic illnesses like diabetes, heart disease, and depression. At the same time, evidence is mounting that combining medical treatment of even severe diseases such as TB and HIV/AIDS with full nutrition can markedly enhance recovery.

So how do we enable and empower people to demand these changes? The most powerful creators of demand for vitality (and thus key target populations) appear to be (1) infants and children (1000 days of pregnancy and infancy, and schoolchildren) and (2) working adults. If they achieve vitality, we believe there will be large, measurable outcome changes: babies will develop far better, schoolchildren will learn more, and workers will be more productive and less apt to get sick – whether they own a small business, or work on a farm or construction site, or in a mine or factory.

The combination for disadvantaged populations of vitality programs and modern ICT systems holds the promise of effective and highly disruptive innovation solutions, and exciting new business, humanitarian, and ongoing rapid learning/research opportunities. Entrepreneurs have demonstrated successful innovations for each of the components of integrated vitality solutions described above. What is needed now is to combine the best into integrated packages that can be locally contextualized and trialed, producing the critical evidence to both improve the approaches and fuel growing demand.

Once tipped towards vitality, this new ecosystem should unleash waves of innovation and investment at which we can only guess. Vitality and nutrient measurement and accounting for consumers and businesses will be provided by new devices and systems. We will see new generations of apps, tools and instruments, and new places where services are dispensed. Successful companies will lead the charge so they have the most vital staff. All the while, new information capture, analysis and distribution systems will generate a spiral of rapid, evidence-based improvement in each of these. New capabilities, professions and business will emerge. People will be empowered to consume wellness/health services effectively. Collections of entrepreneurs will build communities that nourish, including shifting agriculture companies and farming communities toward nutrient generative farming and land management practices.

That is down the road. So what are the challenges today? We need to show what is possible both in outcomes and cost from basic vitality programs. What are the content, business models, and partnering approaches – encompassing but not limited to earlier discovery and treatment of disease – that can achieve widespread vitality, and do so far more efficiently than traditional Western approaches? How is behavioral health done where almost nothing exists? What are the relationships between social entrepreneurs, the citizen and private sectors, and government that can transform the delivery of health to pursue this higher goal? How and where can we catalyze the launch of the multi-partner systemic trials needed to produce the compelling data which will drive change?


We have work to do – together.

Friday, August 26, 2011

A Win-Win: Communications Technology and Global Health

A Win-Win: Communications Technology and Global Health

Just Business (Interview Series)

David K. Aylward, Julia Taylor Kennedy

July 18, 2011

David K. Aylward
David K. Aylward
Julia Taylor Kennedy
Julia Taylor Kennedy


JULIA KENNEDY: Welcome to Just Business, a series of interviews on global business ethics. Today we're talking about ways businesses can use technology to make global health profitable.

David Aylward of Ashoka specializes in a new sector called mobile health, which uses cell phone and other communications technologies to connect poor patients in developing nations to high-level health care.

You are working to educate corporations about the opportunities in these markets. But, David, why don't we start with your work at Ashoka, an NGO that specializes in social enterprise. Tell me how you got to Ashoka and what you do there.

DAVID AYLWARD:
I was invited here several months ago—I've been here three months—to focus on helping them develop health in the developing world, to develop models for the delivery of primary care at the base of the pyramid.

There is a fellow here named Al Hammond who is a leader in that field, and I had been working with him in my last job. When I left the mHealth Alliance, he said, "Come on over to Ashoka and let's work on different models to deliver health."

JULIA KENNEDY: And, of course, Ashoka is known for its social enterprise work. So why don't you explain to our listeners a little bit about the intersection between global health and social enterprise.

DAVID AYLWARD:
There are social entrepreneurs all over the world who have been working on health for a long time, trying to figure out service models for the delivery of health to the poorest people in the world. They have new tools these days, the cell phone and wireless networks, which did not exist until recently. So what we're focused on is the intersection of social entrepreneurs with those new information technologies and then how those can fit together in a broader ecosystem, what we call a hybrid value chain, working with other entities, like wireless carriers, hospitals, insurance companies, and others to deliver a full package of health.

JULIA KENNEDY: Give me an example of how a cell phone can really help augment that package of health.

DAVID AYLWARD:
There are really two levels of it. One, the easiest to understand, is voice, where the ability for someone who is a long distance from a doctor or a hospital can simply pick up their cell phone, call, ask advice, and ask for help, just like we do in this country, where people can give guidance and instructions remotely.

The next level up from that is using it for data, information connections. Wherever you are, information about your electronic health record can be accessed and supplemented. In the not-too-distant future, we will have an array of remote diagnostic devices, monitoring devices, which, connected through your cell phone, will allow unskilled people to diagnose and yourself to diagnose illness at a distance.

JULIA KENNEDY: I heard something about this actually on NPR [National Public Radio] recently about contact lenses as a potential way to do diagnostics. But tell me a little bit about how cell phones can do that and what technology can be embedded to do that.

DAVID AYLWARD:
In my last position at the mHealth Alliance, we gave the Innovation Award for 2011 to a company that had invented a plastic lens that costs about $2 to put onto a cell phone. Then you take a picture of someone's eye, and it produces a prescription for eyeglasses.

JULIA KENNEDY: Wow!

DAVID AYLWARD
: It sends it back to the factory where they make the glasses, and then they ship them out to the person in the field. So, if you can imagine, this would be making eyeglasses accessible to people without having to walk into the city, find an ophthalmologist or an optometrist, and buy them.

JULIA KENNEDY: That's incredible. And how do you start testing these technologies in the field and figuring out how common it is for people to adapt to using them, because I would imagine that's one of the hurdles to get over in the developing world—how do you make sure that they will be adopted?

DAVID AYLWARD:
That's where groups like the social enterprises and Ashoka fellows set-up comes in. They create entities that can test these kinds of systems and devices in the field, figure out what works, what doesn't, feed that back into the global network that we have created and are creating, and then feed that back to manufacturers and others in, hopefully, what will become a more efficient feedback loop.

JULIA KENNEDY: Is the goal to make these products profitable? How do you make sure they're profitable but affordable and balance those incentives?

DAVID AYLWARD
: Great question. That is really the challenge, how you make it sustainable. Once we find systems, devices, and products that have health impact, how do you get those spread out all over the world? The way you do that is you find out what is a sustainable business model to support them. Part of that is getting the price right, getting the price low.

By analogy, if you look at what happened with wireless, here you have devices that got very inexpensive, and service that got very inexpensive. Therefore people in the poorest parts of the world are now paying cash so that they can have access to information. We need to do the same thing in health.

JULIA KENNEDY: To find sort of a leapfrog technology, if you will?

DAVID AYLWARD:
Yes, and pricing. A key to that is what are the global commonalities, so we don't end up trying to produce one set of devices for Tanzania, another set for Kenya, and another set for southern India.

JULIA KENNEDY: How do you go about trying to find that key—a common consumer product that will cross cultures like that?

DAVID AYLWARD:
You work with networks. For example, Ashoka has more than 600 health fellows, and there are lots of people like that around the world. The wonder of the Internet is that we can connect them in real time and have these conversations, if you try. If you go looking for that conversation, you can find it. That is exactly one of the roles that we're undertaking.

JULIA KENNEDY: Tell me how you got into public health. We were chatting a little bit before we started recording this interview, and you said you largely have a background in communications. You've been legislative director to U.S. Representative Timothy Wirth. You've worked with competition in telecommunications with the breakup of AT&T, so that maybe explains some of the mobile piece. But how did all of this really wide-ranging career come together with this public health mission?

DAVID AYLWARD:
It's funny because sometimes people think I planned it, and I didn't. I just kept doing interesting things, one after the other, and ended up here. I spent about 15 years working on emergency response and emergency medicine in the United States, and how to use the wireless and modern information technologies to do that.

Then two years ago I was asked to head the mHealth Alliance, which is hosted by the UN Foundation and supported by the Rockefeller Foundation and Vodafone Foundation and others. So I had the privilege for two years of starting a new organization to globally take advantage of wireless and the linkage to health, so I got to learn a lot about what is possible and who needs to be at the table.

It's a fascinating area, because there's no one group that can do it by itself. Health people can't do it by themselves. They need to be working with the IT industry and the wireless industry. And they need to be working with the pharmaceutical industry and social entrepreneurs. So it is a very rich ecosystem which is exciting, and there is a lot to be learned there. On the other hand, it is very complicated and these groups are not used to working together.

JULIA KENNEDY: So communication becomes very key, right?

DAVID AYLWARD:
Yes. The nice thing about the communication and the wireless is it's brand new, and so it becomes a neutral reason for people to get together to talk about doing something differently, approaching this in a different manner. So it's a new way to come together to have the conversation. Frankly, most of the conversation is about business models and procedural models and about people issues; it's not about technology. The technology is not that complicated, but the technology provides a reason for people to come together around the table and seek solutions.

JULIA KENNEDY: One of the issues with this kind of technology that I know has been brought up for similar initiatives in rural areas of the United States is that you can talk with a specialist.

It's wonderful to have that kind of access to a specialist that might not be within reasonable driving distance of your home over Skype or something, which is a very basic level of the type of communications that you've been talking about. But one of the issues there is there are certain limitations to that type of long-distance communication, right?
Are some of those discussions happening with these technologies in the developing world, too?

DAVID AYLWARD:
Sure, yes. I think there are two limitations that are important in the example you raised. One is that a cell phone can't operate on anybody, so long-distance communication has its limitations.

The second one is that simply having a remote connection to a doctor is not at all the kind of transformation that we need to have. There are not enough doctors in the world. There are not enough doctors in the United States, much less India, to think that the mere remote access to one is going to solve the problem.

What we need is much more sophisticated information systems that use IT to be the force multiplier of a limited number of doctors and medical professionals. So we need a different system than you sitting across the desk or a TV screen from a doctor.

JULIA KENNEDY: There is also the argument that touch can both transmit information that is difficult to capture over technology, but also can transmit healing properties to someone who is ill. So how to get around that?

DAVID AYLWARD
: A lot of people can touch. The much bigger problem that we face in the developing world is lack of knowledge, that people don't know what to do and that we don't know what to do with them. So being able to diagnose that you have malaria when you're 100 kilometers from the clinic allows us to give you the right medicine 100 kilometers from the clinic.

Most women give birth at home in the developing world. Making sure they know what to do and what are the signs of an emergency—so that the few who need to get to emergency care can do so—is much more important than having all of them go to a birthing facility, for example. Most health can be routinized. Most health can be standardized. If we can find the people who need the more expensive care and sophisticated care, and then get them to it—in other words, use information systems to triage—we will be much better off.

JULIA KENNEDY: We've talked a lot about diagnosis. Let's also talk about pharmaceuticals and how mobile devices can help bridge that gap of making sure people are taking their medicine, making sure they have the right medicine. What are some of the issues that come up in the developing world that can be addressed by these types of technologies with pharmaceuticals?

DAVID AYLWARD:
A great issue, very important area, one we spend a lot of time looking at.

The first one is access to medicines. One of the big issues is stockouts. Because of the lack of good information on inventory, you find that it's very, very common for there to be enough of a medicine in a country but having it not be in the right places. So some places have far too much and some don't have enough.

The second issue is one you alluded to, which is adherence. In the developed and developing worlds, there's a huge problem with getting people to take their medicines. They don't come back for the refill for chronic medicines, or they don't take them on a regular basis. Having a real-time information system can track that, report on it, and measure what's going on. For example, with diabetes, taking your insulin level and your blood every day to see whether you're taking your insulin properly allows keeping track of a patient, and keeping track of what they are supposed to be doing. Plus you can use the system for reminders when they don't.

So today's system in both the developed and the developing world is an intermittent contact with a doctor or a nurse. Every couple of weeks you come in for your appointment. Particularly when you're taking medicine and you have chronic diseases, what you want is a daily contact. That's simply not cost effective or possible in either of these markets. But the wireless technology makes it possible.

JULIA KENNEDY: Again, I'm just throwing out hypotheticals here, but what if you come up against a person or even a culture that eschews taking these daily medications? There is a certain level that you can't get to even with technology, right?

DAVID AYLWARD:
Sure. You look at a culture like ours, which is certainly not a culture that's averse to medicine or taking pills, and we have a huge problem with people complying with what the doctors want them to do. There is both a laziness component, and there's a lack-of-education component. None of those are solved by the mere presence of a cell phone. All of those are made better by the possibility of an information pathway to and from a person all the time.

JULIA KENNEDY: And even an opportunity to communicate that—well, the reason I'm not taking it is there's this side effect.

DAVID AYLWARD
: Yes, exactly.

JULIA KENNEDY: Or a place to go that's easy access.

DAVID AYLWARD
: Exactly.

JULIA KENNEDY: I've heard these kinds of ideas to mobilize technology for public health from a variety of different organizations. You worked on it at mHealth Alliance. You're now at Ashoka. How much communication and coalition building is there within this space? Could there be more?

DAVID AYLWARD:
Not nearly enough. There has to be lots more. I think the best way to describe it is that there is a necessary ecosystem that includes public and private parties, each playing different roles, each of which has a different need. Some have a return-on-capital need, some have a social need, and some have a governmental need. But all of them have different needs, and we need to determine who we need at the table doing what in order to deploy these modern systems.

To be more specific, assuming the presence of an active social entrepreneur serving people at the base of the pyramid, what are their costs, and what are their revenue needs? Those numbers will vary depending on what their IT costs are. What is it going to cost them to have an mHealth system? Well, it will cost them more or less depending on how much the wireless company needs. Then all of that will depend to some degree on how much the pharma company needs. All of that will depend on how much support the government is providing.

So we need all of those people around the table to have a conversation about a new kind of transformed, more intelligent health system, one that's informed by these knowledge systems every step of the way. But in order to make that work, we need folks to plan it. It just doesn't happen on its own.

JULIA KENNEDY: You have a great blog, Gray Thoughts from the Middle Kingdom. In a recent entry you wrote an entry/slash/manifesto about how pharmaceutical companies can really benefit from this mobile wireless technology or from mHealth systems. I am curious if you can summarize that for us here and then also talk about whether you're seeing more interest from pharmaceutical companies in these markets.

DAVID AYLWARD
: What I wrote was that there are four major reasons why pharmaceutical companies should want to try to make these systems happen, why they should want to go out of their way to help create the overall ecosystem beyond their particular narrow self-interest. Because what I argued was that their self-interest will be served by these ecosystems. I wasn't asking for charity; I was asking for enlightened self-interest.

In addition to removing stockouts and learning about compliance issues, the most important thing that they would get out of this is a massive database of electronic health records. Here they could benefit from much broader and inexpensive research on what works and what doesn't work.

If we were successful in having an electronic health record for every person in the world—one of our goals—and if this record was accessible with a cell phone by all the parties that are treating that person and owned by that person, that provides, when you multiply that times millions of individuals, a very large database from which we can really make progress in understanding what works and what doesn't work in health, not just pharmaceuticals but any sort of health.

Now, I should add, what that comment raises is the need to very carefully build privacy and security structures into any such mHealth system, because I am not suggesting for one second that corporations should get access willy-nilly to anybody's personal medical records.

JULIA KENNEDY: Social security numbers, et cetera. Or whatever they may be. I'm sorry I'm so U.S.-centric in that question.

DAVID AYLWARD:
But beyond the numbers, having a database from which we can research the impact on 30-to-35-year-old women of a certain kind of medicine is quite different than having access to those individual women's health records.

JULIA KENNEDY: Sure. The second part of my question is, are you seeing that buy-in start to happen? Are you starting to see any of these medical companies respond?

DAVID AYLWARD:
Yes, a lot of individual trials of individual pieces are using this technology. For example, Novartis has worked very successfully with mHealth to deal with stockouts of antimalarial drugs in Tanzania, and Pfizer has a trial going in a number of countries.

But what we have not seen, and I think where the biggest benefit will come, is what I call integrated systems, where the IT—the information technologies and the wireless—underlies an entire health system linking all the parties in it, so that information flows up and down the continuum of care, not just solving individual issues within it. We haven't yet seen those kinds of integrated systems.

JULIA KENNEDY: Another debate that you often hear about in the public health realm dealing with pharmaceutical companies is that there is an incentive in the pharmaceutical industry to develop, promote, and invest in drugs that are necessary for chronic illnesses, for expensive drugs, and that is often not what's needed as much in the developing world. That vaccines and critical illnesses really need treatments and that pharmaceutical companies aren't responding because that's not where the profit margins lie.

What do you think about that debate? Is it really reflecting what is going on?

DAVID AYLWARD
: I think it's a valid debate. I think it's an important one. We've seen significant success in that area. So folks like GAVI, the Clinton Foundation, Bill Clinton individually, and others have done a terrific job trying to aggregate demand for vaccines—I should mention the Gates Foundation as well—to aggregate global demand so that volume purchasing can drive down prices for the developing world.

We are not going to change the fact that a blockbuster cholesterol drug will make lots more money than a vaccine for measles. But if we aggregate the demand across the developing world for the measles vaccine, then we can drive the price down or we can create interest in manufacturing it.

In a similar way, we want to bring together the demand for wireless for mHealth software, devices, and products, so that those become available at the low prices, and at high quality that we've seen in the underlying wireless systems globally.

JULIA KENNEDY: What's next in terms of your strategy to develop mHealth databases and to move this to the next step?

DAVID AYLWARD:
We're assembling with other parties trying to get that ecosystem around the table that I was talking about, in Bangladesh, in India, in a couple of other high-profile countries, and then at a global level. We are trying to get the conversation going between leaders of these different pieces of the ecosystem who need to work together to develop an understanding of how they work together. Then we need to have specific plans to put that on the ground in countries, like India-specific programs.

Ashoka has a spinoff called E Health Points—the actual name of the company is Health Point Services. This is a for-profit clinic model that is now being demonstrated in the Punjab of India, where for very, very small amounts of money people can get diagnostics and see a doctor over a video link. We are adding mHealth to that, and then we will be working with other partners to build a full ecosystem around that. But it is through examples of that kind that we think can show how mHealth can be brought to scale both abroad and, frankly, in this country.

JULIA KENNEDY: Why are India and Bangladesh good places to start?

DAVID AYLWARD:
They have excellent wireless coverage. They have massive needs in this area. And they have very, very strong in-country leadership. There are very strong NGOs in both countries that want to be involved. There are very strong Ashoka fellows that want to be involved. As I mentioned, there is a Health Point Services, which is an Ashoka spinoff, a social business, in India. We have very, very strong interest in both countries in taking advantage of this, both for rural areas but also for the urban poor.

JULIA KENNEDY: When you were at mHealth, you partnered with Health Point Services back in 2009, right? How have you seen that kind of take off over the last couple of years?

DAVID AYLWARD: It's very interesting. That's why I came here, because I already knew about them. They have developed a for-profit, successful model combining the sale of clean water and health services. I think one of the insights that we and others are having is that we need to be focused on more than health care. We need to be focused on wellness, keeping people well. So combining clean water with health for starters was a good model. Finding a for-profit model that works addresses the sustainability issue. So, for both reasons, I was attracted to working with these folks.

JULIA KENNEDY: I can imagine you have to be measuring the impact to look and see if you can scale this elsewhere.

DAVID AYLWARD:
Yes. You are really trying to measure two impacts. You're trying to measure the health impact, on the one hand, but also the economic impact, on the other. If you have a model that is making money, that is supporting itself, almost by definition it has the possibilities of scaling. So part of this is how to figure out that side of the equation, while we're working with global and regional experts on the health side.

JULIA KENNEDY: Why public health? Why does this speak to you? Why have you stayed in it, and why are you passionate about it?

DAVID AYLWARD:
I have always been passionate about the power of information technologies to improve society. That is really the thread that runs throughout my career, from understanding the value of opening up to the very powerful forces of competition, opening up our market to that in the 1970s and 1980s when we used to have a monopoly here. We've seen the power of that globally. Having more than one provider of wireless in most of these countries is the reason that we have this wireless revolution across the world, that unleashing of competition.

About 15 years ago, I got interested in the application in emergency response in medicine and saw what was possible. And today, globally, we have this enormous challenge of chronic disease, on the one hand, which is challenging the United States and developed countries. At the same time we have in the developing world the problem of access to quality medicine.

The old systems simply cannot work. They are not going to work. So there is an opportunity to apply to this new problem of the tidal wave of chronic disease, and the old problem of access to medicine from these new technologies. That is very, very exciting to me.

JULIA KENNEDY: After listening to you for half an hour, it's exciting to me, too. Thank you so much for explaining it and for coming onto Just Business.

DAVID AYLWARD
: Thank you very much.

Read More: Business, Development, Ethics in Business, Global Public Health, Technology, World Poverty, Global


Thursday, June 30, 2011

Why Pharma should invest in delivering mHealth

There are at least two global industries that share the vision of a powerful, integrated and interoperable, person-based, digital health system — powered by the wireless explosion — that touches every person in rural areas and slums in the world (particularly the billions of people in developing countries). These are the wireless and the pharmaceutical industries.

It won’t just happen. Pharma needs to invest in the systems vision for mHealth.

Most people would not scratch their heads about that assertion regarding wireless. But pharma?

Yes, pharma.

As the Executive Director of the mHealth Alliance for the past two years, I focused on how to get mHealth designed and deployed in the most impactful way possible. One part of that mission was looking for those businesses that might help lead this transformation and why they might do so in their own business interests – not just for PR or charity. I became increasingly convinced that the pharmaceutical industry should benefit enormously from the success of mHealth in four ways, described below.

But it won’t just happen. The US is a perfect example of the horrible that happen with willy-nilly investment in digital technology. Pharma needs to invest in the systems vision. Concurrently, those of us seeking to improve health for disadvantaged people would do well to overcome whatever suspicions we might have about drug companies and seek some common ground.

The first area of major intersection between mHealth and pharma is supply chain. This is a terrible problem for public health providers. Drug stock-outs are absurdly common, even when the aggregate supply in a country is sufficient. For much of the developing world, companies don’t know where their products are flowing, or at what price (nor do public health leaders). Simple data tracking using mobile devices is already proving to be the solution for both sets of problems, for example, SMS for Life has had a major positive impact on stock-outs of anti-malarials in Tanzania. http://enterprise.vodafone.com/discover_global_enterprise/sustainability/innovating_together/health_solutions/

Those of us seeking to improve health for disadvantaged people would do well to overcome whatever suspicions we might have about drug companies and seek some common ground

In the future, mHealth can be used to prevent corruption, the paying of bribes to get quality drugs that should be available, or overpaying. People will be able to check prices as well as pay by cell phone, thus taking cash out of the transaction, and reducing transaction costs and opportunities for corruption.

The second area is quality. Counterfeiting is an enormous and very dangerous health problem. Across the developing world, very high percentages of drugs are fake or adulterated. The US-based Center for Medicines in the Public Interest projected a few years ago that by the end of last year, US $75 billion worth of counterfeit drugs would be sold annually. http://www.theghanaianjournal.com/2010/11/09/substandard-and-counterfeit-antimalarial-drugs-discovered-in-ghana/.

A recent report said that more than 13 key anti-malarials in Ghana were substandard or counterfeit. http://www.theghanaianjournal.com/2010/11/09/substandard-and-counterfeit-antimalarial-drugs-discovered-in-ghana/

Counterfeit drugs damage people’s health; they also harm corporate brands and reputations. A handful of innovative mHealth solutions are being adopted that allow providers and consumers to use their cell phones to find out immediately if a drug is genuine.

See www.mPedigree.net and www.sproxil.com. Both emerged from sub-Saharan Africa.
The third area where the pharmaceutical industry stands to benefit enormously from the success of mHealth is adherence. Both public health and drug company profits suffer because high percentages of patients do not comply with their drug regimens.

The following is one of thousands of articles written on the subject. http://press.novonordisk-us.com/bluesheet-issue3/downloads/NovoNordisk_Bluesheet_October2010_ItTakesAVillage.pdf

Some don’t fill the prescription initially; others don’t get refills. Some stop when they feel better. We don’t have the answers yet, but experts are excited about using the new wireless pathway to people to measure and improve compliance, both directly and through social networks and reminders. The key to figuring out what improves compliance is a lot of field tests and research, which are much easier to do if the fourth key interest of pharma in mHealth (an electronic record systems tracking all of a person’s health events and information) is in place.

The fourth area is usage. A core component of any digital/mHealth system has to be a record of who the patients are, what issues they have, what is done for them, and what the outcomes are – in other words, a personal, persistent, comprehensive electronic health record. A primary goal of mHealth initiatives is to get systems deployed at scale so that hundreds of millions of people in emerging economies have electronic health records (EHR), accessible to them and their providers through cell phones as well as computers.

Simple mHealth systems can have a major positive impact on the delivery of care by linking an EHR to relatively simple features like a calendar, reminder messages, patient interview/screening templates and checklists. In most developing countries, the absence of legacy health information technology systems means that these new systems could capture a patient’s record in its entirety, not merely the slices and dices available in the developed world from any single source.

The byproduct of this more efficient care system will be an enormous amount of extremely valuable data about health. And that will be end-to-end data about patients, unlike the US, where our entirely balkanized system (each doctor, lab and hospital have their own paper or electronic data silo on the patient) makes it difficult or impossible to get the full picture for one patient, much less millions. We will have to establish policies and systems to properly anonymize this data to protect privacy.

From a researcher’s point of view, whether they are an academic, a WHO specialist, or a pharmaceutical developer, this will create a gold mine of data on actions and outcomes that can be reviewed efficiently, effectively in real time. Very large test cohorts can be created cheaply and rapidly.

We are excited because this basic mHealth system will allow us to learn which interventions work and which don’t, and learn fast (e.g. how we can motivate people to take all their pills correctly). We will be able to establish systems of continuous improvement using our operations data – just like every other serious enterprise in the world. We won’t have to spend large amounts of additional money creating tests and special test data. Most importantly, we won’t have to wait years for analysis as we do today.

Pharma can piggy back on systems delivering care, and get appropriate usage and outcome data about patients

And pharma? They will get the same benefits. They spend large amounts of money to achieve equivalent results today: creating field trials, and buying usage data of various kinds from disparate sources. But here they can piggy back on systems delivering care, and get appropriate usage and outcome data about patients. (Obviously, policies and systems will have to be put in place to protect individual rights.) This is particularly important as the costs of research/trials are rising just as the need to replace blockbuster drugs with expiring patents becomes more acute.

In the future, I imagine pharma will be just one of several important business players in the digital health eco-system at the base of the pyramid. In the future, they will probably be happy to pay substantial sums to others for appropriate anonymized data for research, thus contributing to sustainable systems.

But today, if I were pharma, I would adopt a much more activist “make it happen” role to ensure that these integrated, interoperable systems are developed and deployed. Those of us who care about health at the base of the pyramid have some very good reasons to work with the pharmaceutical industry as one of the critical initial investors in these promising new technologies.

******

I wrote these comments at the request of SARPAM, a neat organization funded by the UK foreign aid agency focused on public health in Africa. Check out their website. http://www.sarpam.net/what-the-experts-say/the-intersection-of-global-mhealth-and-pharma/

Monday, June 13, 2011

The New Economy Movement

Gar Alperovitz just wrote an interesting article in the June 13 issue of the Nation about how growth economics needs to be re-thought in the face of environmental crisis and distributional inequities.

Here is a link to the article.

https://docs.google.com/a/daylward.org/viewer?a=v&pid=explorer&chrome=true&srcid=0BwnUEPzIHH0AZjgwZDVlMGItMDkwYi00ZGFjLTg1OTEtNTE0ODE3NDQzYWFi&hl=en_US

This is worth reading as a survey of interesting experiments going on in the US. And there are some very interesting ideas here, e.g. new forms of measuring GDP that measure all the real costs of production, versus allowing many companies to export many of their costs onto society in the form of pollution, abuse of workers, etc. That would be worth funding, and then making a big deal issuing restatements of financials for large international companies every quarter based on this green, sustainable standard. “If you really paid the real costs of your business, you would have lost money” etc. This would infuriate some companies and get others to respond.

I find the article lacking in three important areas:

a. 1. It dismisses the incredibly powerful wealth creation engine of capitalism as if that argument is not worth having. I think it is worth having a serious discussion as to whether a combination of regulation to make production reflect its actual costs (e.g. taxing they type of energy used to cover the costs of global warming), and redistributional taxation (to eliminate inequalities, within countries and between countries), might capture the obvious wealth generation benefits of capitalism, while cutting its costs.

b. 2. It only implicitly talks about the elephant in the room: convincing the top half of Americans to live with less, and the bottom half not to aspire to more than that. I have helped establish and run worker-owned companies. Merely changing ownership doesn’t change motives. There is a fundamental value change that has to happen related to the sizes of our houses, cars and closets. How do we do begin that conversation?

c. 3. Most important, the article is entirely US-centric, and thus North/developed country-specific. It mentions a British group once in passing. A good socialist like Gar needs to remember the International. Seriously, how can we think about the developing world? The answer that poor villagers in India and Mali should be happy with Jeffersonian sustainable rural agriculture won’t fly. That pure capitalism has just delivered wireless communications into the hands of most people world wide might give us pause here. However, that happened in part due to a leap frog (over wired communications). In the same way that we are pursuing leapfrogging the western system in health for these countries, using the new information and communications technologies, maybe the absence of entrenched traditional corporate structures presents an emerging economy option to leap frog destructive, unsustainable practices (although India and China appear to say “no”).

Who are the serious people like Gar Alperovitz working on this for the developing world?

Thursday, March 4, 2010

Serial Impressions of Delhi

Left Dulles Airport at 10 p.m. Tuesday; arrived in Frankfurt at 11:30 a.m. Wednesday, and landed in Delhi at 1:30 a.m. Thursday. My window seat across central Europe, Georgia, Caspian Sea, Iran, Afghanistan and Pakistan was wasted as I slept through the daylight hours.


Knew I was in India when 4 very large Brahma bulls walked across a main street near the hotel.

Worked all morning and until 1:30 then decided to be adventurous. Walking toward Connaught Circle, a mile away, I was struck by the filthy air and the partial/stopped/under construction everywhere, including and especially torn up sidewalks. I was picked up by a young man who is clearly in the business of guiding tourists around. He suggested a government run emporium first, waiting outside. I looked at the wares, walked out and told my guide that I wanted to take the Metro to the Red Fort (a prominent part of the history of the seige of Delhi I had read a year ago). "No, no. You need motorcycle rickshaw". Having recently experienced the death defying Bangkok tuk tuk, I thought I knew what I was in for. Not.


He made a call on his cell phone -- everyone is carrying one. in 5 minutes Kumar appeared. Later I learned he is Hindu, was born in 1946 in Pakistan, and fled with his family to Delhi after the partition of 1947. He has been driving a motorcycle rickshaw for 42 years -- and is really good at it, in the same way that Lesley Vonn is really good at downhill (but you don't want to be sitting on her shoulders). Kumar agreed to take me to the Red Fort, the Jama Masjid Mosque, key graves and a store, for as long as I wanted, for 340 rupees (about $7.50).


Off we roared. We were shortly in the old city of Delhi. Imagine K Street in Washington at 11 a.m. Keep the same number of cars and buses (but the buses are really old); drop in motorcycles at 3-4x the number of cars, motorcycle rickshaws, bicycle rickshaws, and bicycles each the same number as cars; and then have pedestrians walking into the streets all along the block, wending their way through the traffic. Then have all those with horns use them at least twice a minute.


I hung on for dear life as Kumar accelerated into this maelstrom. Every couple of minutes we came within inches of smashing someone or being smashed, but Kumar always somehow avoided disaster.


Our first stop was the enormous Jama Masjid Mosque built in 1656 by the Emperor Shah Jahan, who also built the Taj Mahal. Built high up, with three marble domes covering the prayer hall and a large open area with a pool in the middle for bathing before prayer, it can hold 20,000 people in prayer. Shedding my shoes and socks, donning a full length skirt to cover up my bare legs from shorts, and paying my 200 rupee fee ($5) to take pictures, I was taken over by another guide -- a short, animated, intense guy who spent 45 minutes teaching me about the place entirely with grunts, gestures and facial expressions.


We walked on the prayer rugs under the domes; he showed me the pock marks on the exterior walls created by bullets in some attack; he showed me the cracks and destruction from an earthquake (throwing his hands in the air); he pointed out the sheep for sacrifice grazing on the roofs of some buildings below; he trotted me way up one of the minarets for a birds eye view of Delhi. It must have been a couple of hundred steps in a tight circular upward path.


At the top, I joined 8 other tourists, precariously perched on some of the 18 inch wide circle of stone around the open hole of the stairs down. OSHA would close it down. I took pictures from all directions, especially the long line of the walls of the Red Fort, but the air was so dirty I don't think they will show much.


Back down on the main level, my guide took me to the far corner, where in a room in the wall, women were allowed to pray. He called the head guy in the front, who moved the women forward, and proceeded to open the large padlock on a large white wooden chest at the back of the room. The head guy crawled into the space. I was told to stand and watch, as the guide told the curious crowd to stand back.


The head guy spoke reasonable English . I was amazed when he proceeded to share with me the holy relics of the Mosque. I have no idea whether these are genuine, but it was amazing to have them presented to me. The first was a fragment of the Koran written on deer skin by Ali, son in law of the Prophet, and founder of the Shiite faith. The other part of it, he said, is in a museum in Istanbul. The second relic is another part of the Koran written on deer skin by Mohammed's grandson. The third was a long, beard hair of the Prophet, mounted in an airtight glass case. The fourth was the remains of his right sandal. The final relic was a foot print of the right foot of Mohammed; again the other is in the Istanbul Museum.


Throughout the presentation, both my guide and this head guy kept shooing the curious locals back. Go figure. On request for a contribution of some sort, I was happy to contribute 200 rupees.


Off to the Red Fort. It is an enormous sandstone structure covering 10s of acres with walls 60 feet high or more. Kumar apparently has a very low opinion of it (and there is clearly no convenient parking), because he told me the only thing I should do is photograph the front gate quickly as we turned at the closest intersection. He said my 500 rupee ticket to get in would show me nothing. Based on the book I read, I think he is wrong, but I wasn't going to fight my tour guide.


At an intersection an 8 or 9 year old boy squirmed his way into the middle of the stopped traffic to try to sell cheap plastic pens. He tried to force them on me. When I refused, and the traffic started to move, his hand darted to the seat next to me and stole the postcard of the Mosque I had been given by my tour guide there.


Everywhere I am struck by the number of people, almost invariably men, who are standing, sitting or lounging on the streets, apparently doing nothing. In stark contrast are men straining on the pedals of bicycle rickshaws overloaded with stuff, and men straining to pull and push two wheel carts with enormous loads.

I see 30 men squatting in a row, each with a bag of tools, ready to be hired for carpentry work. I see rows of bicycle mechanics working by the roadside fixing bikes and pedicabs. I see innumerable tiny pharmacies and dental offices, and then an enormous hospital. Once an ambulance goes by. I cannot imagine that there are not trauma injuries occuring every second in the city. Amazingly, everyone on motorbikes is wearing a helmet. Otherwise, this city is a field day for injury prevention specialists. However, this city would clearly grind to a total halt if 20 percent of the drivers drove defensively.


Next stop was the grave of Jahawarl Nehru, the first Prime Minister of India. His ashes are in a mound set in a very large public park that has the remains of all the modern heros of India: mostly the assassinated Gandhis: Mahatma, and Nehru's offspring. The signs at each entrance describe it as "a sacred place", frequented by foreign visitors, and plead with Indians to keep the grounds nice.


Walking to Nehru's grave in this public park, I encountered 4 children, ranging from 3 to 6. One was a naked boy. The eldest tried to beg from me half-heartedly.


I gave my respects to Nehru, who I remember admiring while he lived. His grave is a simple mound of grass, backed by a stone wall with quotations from him. Behind it is the grave of his assasinated grandson, Sanjay Gandhi. It is in a park with a pond. What a contrast from old Delhi from which I had just come! Walking out by a different route, I came upon a 3-4 year old girl standing in front, crying. That has bothered me ever since. I didn't know what to do. In the US I would have picked up the child, found a social services office, and turned her over. Here I simply did the stupid thing of greeting her and trying to make her smile.


Two hundred yards, and five kids with whom I could have pulled a Madonna.


Driving down the road next to the park we passed large gates with signs for the graves of Indira Gandhi and then her son, Rajiv. Then we arrive at the memorial to the founder of modern India, Mahatma Gandhi. A long walkway with fountains leads to a raised berm in a square with a walkway on top to look down on a 100 square yard place in the middle of which is a large two foot think black granite slab with his initials and flowers on top, next to an eternal gas light flame. After taking pictures and having them taken of me, I went around to the side where no one was, kneeled, and gave thanks for the man of my century who I believe is closest to a saint.


Diving into more terrifying traffic we suddenly were on a four lane overpass, over another four lane road. Kumar shouted to me: "Delhi yesterday (with his thumb pointing back); Delhi today (pointing down at the bridge)". Indeed, it was the proverbial two sides of the tracks. We went to see the Krishna Temple, a modern Hindu temple, passing loads of apartments, government buildings, schools and the like.


Kumar then delivered me to the tourist shop. Presumably he gets a cut on whatever I spend there. He waits outside. I am warmly greeted by a phalanx of highly motivated salespeople.

Basement is rugs, first floor curios and women's bags, second floor women's garments, and third floor bronze curios (including to die for large elephants like I climbed on as a child, but my grandmother left to my cousins). Great stuff. I am jumped on by Omar, a super salesman originally from Kashmir. He makes the guy (of the same age and style) in Bangkok a month ago (who got up to 6 suits and 15 shirts before I escaped) look like a rank amateur. Omar proceeds to tell me about wool from under the neck of baby goats (where it has no exposure to rain or sun), about girls who spent two months embroidering the single traditional Indian tunic I should buy, about families that spend not 3 or 4, but 3 1/2 years making a single rug, about them tearing up patterns so the rug is unique.

I make it clear that I can't buy a rug without consultation. I take pictures. The price on an amazing Kashmiri 6X9 keeps coming down. It started at $2700. I have an offer of $1500 including VAT and shipping as I walk out the door.

When I escape and get back in the motorcycle rickshaw, Kumar says: "Why didn't you buy the rug?" I roar with laughter and explain. He goes back to talk with the gaggle of men sitting on plastic chairs outside the store, returns, and off we go.

We pass a quarter mile of stables of city draft horses along a main road, just before the huge international hotel where 12 field hockey teams are staying now for the World Championships.

What a day! Back to hotel, swim in a very cold pool, steam room for a while, cold shower and wonderful Indian dinner. Hours more calls and work. Life is good.

Sunday, May 31, 2009

Superb thinking on medical cost control

The author here is amazingly influential (couple of wonderful books I strongly recommend; both are short, accessible and packed with insight: “Complications” and “Better”). Doctor in Boston and New Yorker’s health correspondent for years. Has spent lots of time with the Clinton and Obama crowds.

This is a really powerful, thoughtful article. Even if you don’t care much about health care reform, this is an excellent read. He uses a couple of specific places (a town in Texas; Colorado; Mayo) to make a series of critical points about health care.

The Dartmouth Medical School studies are critical to understanding the new Administration’s approach to cost control. Those studies are OMB Director Peter Orszag’s bible to getting a handle on health care costs. In short, the studies have been showing that there are wilding varying differences in levels of treatment and thus expenditures for the same diseases around the country, and no correlation of that spending with better medical outcomes.

This explains the focus in the stimulus package on electronic health records to capture exactly what we are doing, $1.1 billion in research by HHS to determine what the data says is the right and cost effective thing(s) to do for each illness, and then down the road incent/only pay for following that protocol.

Best wishes to all!

Annals of Medicine: The Cost Conundrum (The New Yorker)

What a Texas town can teach us about health care.

By Atul Gawande

June 1, 2009

It is spring in McAllen, Texas. The morning sun is warm. The streets are lined with palm trees and pickup trucks. McAllen is in Hidalgo County, which has the lowest household income in the country, but it’s a border town, and a thriving foreign-trade zone has kept the unemployment rate below ten per cent. McAllen calls itself the Square Dance Capital of the World. “Lonesome Dove” was set around here.

McAllen has another distinction, too: it is one of the most expensive health-care markets in the country. Only Miami—which has much higher labor and living costs—spends more per person on health care. In 2006, Medicare spent fifteen thousand dollars per enrollee here, almost twice the national average. The income per capita is twelve thousand dollars. In other words, Medicare spends three thousand dollars more per person here than the average person earns.

The explosive trend in American medical costs seems to have occurred here in an especially intense form. Our country’s health care is by far the most expensive in the world. In Washington, the aim of health-care reform is not just to extend medical coverage to everybody but also to bring costs under control. Spending on doctors, hospitals, drugs, and the like now consumes more than one of every six dollars we earn. The financial burden has damaged the global competitiveness of American businesses and bankrupted millions of families, even those with insurance. It’s also devouring our government. “The greatest threat to America’s fiscal health is not Social Security,” President Barack Obama said in a March speech at the White House. “It’s not the investments that we’ve made to rescue our economy during this crisis. By a wide margin, the biggest threat to our nation’s balance sheet is the skyrocketing cost of health care. It’s not even close.”

The question we’re now frantically grappling with is how this came to be, and what can be done about it. McAllen, Texas, the most expensive town in the most expensive country for health care in the world, seemed a good place to look for some answers.

From the moment I arrived, I asked almost everyone I encountered about McAllen’s health costs—a businessman I met at the five-gate McAllen-Miller International Airport, the desk clerks at the Embassy Suites Hotel, a police-academy cadet at McDonald’s. Most weren’t surprised to hear that McAllen was an outlier. “Just look around,” the cadet said. “People are not healthy here.” McAllen, with its high poverty rate, has an incidence of heavy drinking sixty per cent higher than the national average. And the Tex-Mex diet has contributed to a thirty-eight-per-cent obesity rate.

One day, I went on rounds with Lester Dyke, a weather-beaten, ranch-owning fifty-three-year-old cardiac surgeon who grew up in Austin, did his surgical training with the Army all over the country, and settled into practice in Hidalgo County. He has not lacked for business: in the past twenty years, he has done some eight thousand heart operations, which exhausts me just thinking about it. I walked around with him as he checked in on ten or so of his patients who were recuperating at the three hospitals where he operates. It was easy to see what had landed them under his knife. They were nearly all obese or diabetic or both. Many had a family history of heart disease. Few were taking preventive measures, such as cholesterol-lowering drugs, which, studies indicate, would have obviated surgery for up to half of them.

Yet public-health statistics show that cardiovascular-disease rates in the county are actually lower than average, probably because its smoking rates are quite low. Rates of asthma, H.I.V., infant mortality, cancer, and injury are lower, too. El Paso County, eight hundred miles up the border, has essentially the same demographics. Both counties have a population of roughly seven hundred thousand, similar public-health statistics, and similar percentages of non-English speakers, illegal immigrants, and the unemployed. Yet in 2006 Medicare expenditures (our best approximation of over-all spending patterns) in El Paso were $7,504 per enrollee—half as much as in McAllen. An unhealthy population couldn’t possibly be the reason that McAllen’s health-care costs are so high. (Or the reason that America’s are. We may be more obese than any other industrialized nation, but we have among the lowest rates of smoking and alcoholism, and we are in the middle of the range for cardiovascular disease and diabetes.)

Was the explanation, then, that McAllen was providing unusually good health care? I took a walk through Doctors Hospital at Renaissance, in Edinburg, one of the towns in the McAllen metropolitan area, with Robert Alleyn, a Houston-trained general surgeon who had grown up here and returned home to practice. The hospital campus sprawled across two city blocks, with a series of three- and four-story stucco buildings separated by golfing-green lawns and black asphalt parking lots. He pointed out the sights—the cancer center is over here, the heart center is over there, now we’re coming to the imaging center. We went inside the surgery building. It was sleek and modern, with recessed lighting, classical music piped into the waiting areas, and nurses moving from patient to patient behind rolling black computer pods. We changed into scrubs and Alleyn took me through the sixteen operating rooms to show me the laparoscopy suite, with its flat-screen video monitors, the hybrid operating room with built-in imaging equipment, the surgical robot for minimally invasive robotic surgery.

I was impressed. The place had virtually all the technology that you’d find at Harvard and Stanford and the Mayo Clinic, and, as I walked through that hospital on a dusty road in South Texas, this struck me as a remarkable thing. Rich towns get the new school buildings, fire trucks, and roads, not to mention the better teachers and police officers and civil engineers. Poor towns don’t. But that rule doesn’t hold for health care.

At McAllen Medical Center, I saw an orthopedic surgeon work under an operating microscope to remove a tumor that had wrapped around the spinal cord of a fourteen-year-old. At a home-health agency, I spoke to a nurse who could provide intravenous-drug therapy for patients with congestive heart failure. At McAllen Heart Hospital, I watched Dyke and a team of six do a coronary-artery bypass using technologies that didn’t exist a few years ago. At Renaissance, I talked with a neonatologist who trained at my hospital, in Boston, and brought McAllen new skills and technologies for premature babies. “I’ve had nurses come up to me and say, ‘I never knew these babies could survive,’ ” he said.

And yet there’s no evidence that the treatments and technologies available at McAllen are better than those found elsewhere in the country. The annual reports that hospitals file with Medicare show that those in McAllen and El Paso offer comparable technologies—neonatal intensive-care units, advanced cardiac services, PET scans, and so on. Public statistics show no difference in the supply of doctors. Hidalgo County actually has fewer specialists than the national average.

Nor does the care given in McAllen stand out for its quality. Medicare ranks hospitals on twenty-five metrics of care. On all but two of these, McAllen’s five largest hospitals performed worse, on average, than El Paso’s. McAllen costs Medicare seven thousand dollars more per person each year than does the average city in America. But not, so far as one can tell, because it’s delivering better health care.

One night, I went to dinner with six McAllen doctors. All were what you would call bread-and-butter physicians: busy, full-time, private-practice doctors who work from seven in the morning to seven at night and sometimes later, their waiting rooms teeming and their desks stacked with medical charts to review.

Some were dubious when I told them that McAllen was the country’s most expensive place for health care. I gave them the spending data from Medicare. In 1992, in the McAllen market, the average cost per Medicare enrollee was $4,891, almost exactly the national average. But since then, year after year, McAllen’s health costs have grown faster than any other market in the country, ultimately soaring by more than ten thousand dollars per person.

“Maybe the service is better here,” the cardiologist suggested. People can be seen faster and get their tests more readily, he said.

Others were skeptical. “I don’t think that explains the costs he’s talking about,” the general surgeon said.

“It’s malpractice,” a family physician who had practiced here for thirty-three years said.

“McAllen is legal hell,” the cardiologist agreed. Doctors order unnecessary tests just to protect themselves, he said. Everyone thought the lawyers here were worse than elsewhere.

That explanation puzzled me. Several years ago, Texas passed a tough malpractice law that capped pain-and-suffering awards at two hundred and fifty thousand dollars. Didn’t lawsuits go down?

“Practically to zero,” the cardiologist admitted.

“Come on,” the general surgeon finally said. “We all know these arguments are bullshit. There is overutilization here, pure and simple.” Doctors, he said, were racking up charges with extra tests, services, and procedures.

The surgeon came to McAllen in the mid-nineties, and since then, he said, “the way to practice medicine has changed completely. Before, it was about how to do a good job. Now it is about ‘How much will you benefit?’ ”

Everyone agreed that something fundamental had changed since the days when health-care costs in McAllen were the same as those in El Paso and elsewhere. Yes, they had more technology. “But young doctors don’t think anymore,” the family physician said.

The surgeon gave me an example. General surgeons are often asked to see patients with pain from gallstones. If there aren’t any complications—and there usually aren’t—the pain goes away on its own or with pain medication. With instruction on eating a lower-fat diet, most patients experience no further difficulties. But some have recurrent episodes, and need surgery to remove their gallbladder.

Seeing a patient who has had uncomplicated, first-time gallstone pain requires some judgment. A surgeon has to provide reassurance (people are often scared and want to go straight to surgery), some education about gallstone disease and diet, perhaps a prescription for pain; in a few weeks, the surgeon might follow up. But increasingly, I was told, McAllen surgeons simply operate. The patient wasn’t going to moderate her diet, they tell themselves. The pain was just going to come back. And by operating they happen to make an extra seven hundred dollars.

I gave the doctors around the table a scenario. A forty-year-old woman comes in with chest pain after a fight with her husband. An EKG is normal. The chest pain goes away. She has no family history of heart disease. What did McAllen doctors do fifteen years ago?

Send her home, they said. Maybe get a stress test to confirm that there’s no issue, but even that might be overkill.

And today? Today, the cardiologist said, she would get a stress test, an echocardiogram, a mobile Holter monitor, and maybe even a cardiac catheterization.

“Oh, she’s definitely getting a cath,” the internist said, laughing grimly.

To determine whether overuse of medical care was really the problem in McAllen, I turned to Jonathan Skinner, an economist at Dartmouth’s Institute for Health Policy and Clinical Practice, which has three decades of expertise in examining regional patterns in Medicare payment data. I also turned to two private firms—D2Hawkeye, an independent company, and Ingenix, UnitedHealthcare’s data-analysis company—to analyze commercial insurance data for McAllen. The answer was yes. Compared with patients in El Paso and nationwide, patients in McAllen got more of pretty much everything—more diagnostic testing, more hospital treatment, more surgery, more home care.

The Medicare payment data provided the most detail. Between 2001 and 2005, critically ill Medicare patients received almost fifty per cent more specialist visits in McAllen than in El Paso, and were two-thirds more likely to see ten or more specialists in a six-month period. In 2005 and 2006, patients in McAllen received twenty per cent more abdominal ultrasounds, thirty per cent more bone-density studies, sixty per cent more stress tests with echocardiography, two hundred per cent more nerve-conduction studies to diagnose carpal-tunnel syndrome, and five hundred and fifty per cent more urine-flow studies to diagnose prostate troubles. They received one-fifth to two-thirds more gallbladder operations, knee replacements, breast biopsies, and bladder scopes. They also received two to three times as many pacemakers, implantable defibrillators, cardiac-bypass operations, carotid endarterectomies, and coronary-artery stents. And Medicare paid for five times as many home-nurse visits. The primary cause of McAllen’s extreme costs was, very simply, the across-the-board overuse of medicine.

This is a disturbing and perhaps surprising diagnosis. Americans like to believe that, with most things, more is better. But research suggests that where medicine is concerned it may actually be worse. For example, Rochester, Minnesota, where the Mayo Clinic dominates the scene, has fantastically high levels of technological capability and quality, but its Medicare spending is in the lowest fifteen per cent of the country—$6,688 per enrollee in 2006, which is eight thousand dollars less than the figure for McAllen. Two economists working at Dartmouth, Katherine Baicker and Amitabh Chandra, found that the more money Medicare spent per person in a given state the lower that state’s quality ranking tended to be. In fact, the four states with the highest levels of spending—Louisiana, Texas, California, and Florida—were near the bottom of the national rankings on the quality of patient care.

In a 2003 study, another Dartmouth team, led by the internist Elliott Fisher, examined the treatment received by a million elderly Americans diagnosed with colon or rectal cancer, a hip fracture, or a heart attack. They found that patients in higher-spending regions received sixty per cent more care than elsewhere. They got more frequent tests and procedures, more visits with specialists, and more frequent admission to hospitals. Yet they did no better than other patients, whether this was measured in terms of survival, their ability to function, or satisfaction with the care they received. If anything, they seemed to do worse.

That’s because nothing in medicine is without risks. Complications can arise from hospital stays, medications, procedures, and tests, and when these things are of marginal value the harm can be greater than the benefits. In recent years, we doctors have markedly increased the number of operations we do, for instance. In 2006, doctors performed at least sixty million surgical procedures, one for every five Americans. No other country does anything like as many operations on its citizens. Are we better off for it? No one knows for sure, but it seems highly unlikely. After all, some hundred thousand people die each year from complications of surgery—far more than die in car crashes.

To make matters worse, Fisher found that patients in high-cost areas were actually less likely to receive low-cost preventive services, such as flu and pneumonia vaccines, faced longer waits at doctor and emergency-room visits, and were less likely to have a primary-care physician. They got more of the stuff that cost more, but not more of what they needed.

In an odd way, this news is reassuring. Universal coverage won’t be feasible unless we can control costs. Policymakers have worried that doing so would require rationing, which the public would never go along with. So the idea that there’s plenty of fat in the system is proving deeply attractive. “Nearly thirty per cent of Medicare’s costs could be saved without negatively affecting health outcomes if spending in high- and medium-cost areas could be reduced to the level in low-cost areas,” Peter Orszag, the President’s budget director, has stated.

Most Americans would be delighted to have the quality of care found in places like Rochester, Minnesota, or Seattle, Washington, or Durham, North Carolina—all of which have world-class hospitals and costs that fall below the national average. If we brought the cost curve in the expensive places down to their level, Medicare’s problems (indeed, almost all the federal government’s budget problems for the next fifty years) would be solved. The difficulty is how to go about it. Physicians in places like McAllen behave differently from others. The $2.4-trillion question is why. Unless we figure it out, health reform will fail.

I had what I considered to be a reasonable plan for finding out what was going on in McAllen. I would call on the heads of its hospitals, in their swanky, decorator-designed, churrigueresco offices, and I’d ask them.

The first hospital I visited, McAllen Heart Hospital, is owned by Universal Health Services, a for-profit hospital chain with headquarters in King of Prussia, Pennsylvania, and revenues of five billion dollars last year. I went to see the hospital’s chief operating officer, Gilda Romero. Truth be told, her office seemed less churrigueresco than Office Depot. She had straight brown hair, sympathetic eyes, and looked more like a young school teacher than like a corporate officer with nineteen years of experience. And when I inquired, “What is going on in this place?” she looked surprised.

Is McAllen really that expensive? she asked.

I described the data, including the numbers indicating that heart operations and catheter procedures and pacemakers were being performed in McAllen at double the usual rate.

“That is interesting,” she said, by which she did not mean, “Uh-oh, you’ve caught us” but, rather, “That is actually interesting.” The problem of McAllen’s outlandish costs was new to her. She puzzled over the numbers. She was certain that her doctors performed surgery only when it was necessary. It had to be one of the other hospitals. And she had one in mind—Doctors Hospital at Renaissance, the hospital in Edinburg that I had toured.

She wasn’t the only person to mention Renaissance. It is the newest hospital in the area. It is physician-owned. And it has a reputation (which it disclaims) for aggressively recruiting high-volume physicians to become investors and send patients there. Physicians who do so receive not only their fee for whatever service they provide but also a percentage of the hospital’s profits from the tests, surgery, or other care patients are given. (In 2007, its profits totalled thirty-four million dollars.) Romero and others argued that this gives physicians an unholy temptation to overorder.

Such an arrangement can make physician investors rich. But it can’t be the whole explanation. The hospital gets barely a sixth of the patients in the region; its margins are no bigger than the other hospitals’—whether for profit or not for profit—and it didn’t have much of a presence until 2004 at the earliest, a full decade after the cost explosion in McAllen began.

“Those are good points,” Romero said. She couldn’t explain what was going on.

The following afternoon, I visited the top managers of Doctors Hospital at Renaissance. We sat in their boardroom around one end of a yacht-length table. The chairman of the board offered me a soda. The chief of staff smiled at me. The chief financial officer shook my hand as if I were an old friend. The C.E.O., however, was having a hard time pretending that he was happy to see me. Lawrence Gelman was a fifty-seven-year-old anesthesiologist with a Bill Clinton shock of white hair and a weekly local radio show tag-lined “Opinions from an Unrelenting Conservative Spirit.” He had helped found the hospital. He barely greeted me, and while the others were trying for a how-can-I-help-you-today attitude, his body language was more let’s-get-this-over-with.

So I asked him why McAllen’s health-care costs were so high. What he gave me was a disquisition on the theory and history of American health-care financing going back to Lyndon Johnson and the creation of Medicare, the upshot of which was: (1) Government is the problem in health care. “The people in charge of the purse strings don’t know what they’re doing.” (2) If anything, government insurance programs like Medicare don’t pay enough. “I, as an anesthesiologist, know that they pay me ten per cent of what a private insurer pays.” (3) Government programs are full of waste. “Every person in this room could easily go through the expenditures of Medicare and Medicaid and see all kinds of waste.” (4) But not in McAllen. The clinicians here, at least at Doctors Hospital at Renaissance, “are providing necessary, essential health care,” Gelman said. “We don’t invent patients.”

Then why do hospitals in McAllen order so much more surgery and scans and tests than hospitals in El Paso and elsewhere?

In the end, the only explanation he and his colleagues could offer was this: The other doctors and hospitals in McAllen may be overspending, but, to the extent that his hospital provides costlier treatment than other places in the country, it is making people better in ways that data on quality and outcomes do not measure.

“Do we provide better health care than El Paso?” Gelman asked. “I would bet you two to one that we do.”

It was a depressing conversation—not because I thought the executives were being evasive but because they weren’t being evasive. The data on McAllen’s costs were clearly new to them. They were defending McAllen reflexively. But they really didn’t know the big picture of what was happening.

And, I realized, few people in their position do. Local executives for hospitals and clinics and home-health agencies understand their growth rate and their market share; they know whether they are losing money or making money. They know that if their doctors bring in enough business—surgery, imaging, home-nursing referrals—they make money; and if they get the doctors to bring in more, they make more. But they have only the vaguest notion of whether the doctors are making their communities as healthy as they can, or whether they are more or less efficient than their counterparts elsewhere. A doctor sees a patient in clinic, and has her check into a McAllen hospital for a CT scan, an ultrasound, three rounds of blood tests, another ultrasound, and then surgery to have her gallbladder removed. How is Lawrence Gelman or Gilda Romero to know whether all that is essential, let alone the best possible treatment for the patient? It isn’t what they are responsible or accountable for.

Health-care costs ultimately arise from the accumulation of individual decisions doctors make about which services and treatments to write an order for. The most expensive piece of medical equipment, as the saying goes, is a doctor’s pen. And, as a rule, hospital executives don’t own the pen caps. Doctors do.

If doctors wield the pen, why do they do it so differently from one place to another? Brenda Sirovich, another Dartmouth researcher, published a study last year that provided an important clue. She and her team surveyed some eight hundred primary-care physicians from high-cost cities (such as Las Vegas and New York), low-cost cities (such as Sacramento and Boise), and others in between. The researchers asked the physicians specifically how they would handle a variety of patient cases. It turned out that differences in decision-making emerged in only some kinds of cases. In situations in which the right thing to do was well established—for example, whether to recommend a mammogram for a fifty-year-old woman (the answer is yes)—physicians in high- and low-cost cities made the same decisions. But, in cases in which the science was unclear, some physicians pursued the maximum possible amount of testing and procedures; some pursued the minimum. And which kind of doctor they were depended on where they came from.

Sirovich asked doctors how they would treat a seventy-five-year-old woman with typical heartburn symptoms and “adequate health insurance to cover tests and medications.” Physicians in high- and low-cost cities were equally likely to prescribe antacid therapy and to check for H. pylori, an ulcer-causing bacterium—steps strongly recommended by national guidelines. But when it came to measures of less certain value—and higher cost—the differences were considerable. More than seventy per cent of physicians in high-cost cities referred the patient to a gastroenterologist, ordered an upper endoscopy, or both, while half as many in low-cost cities did. Physicians from high-cost cities typically recommended that patients with well-controlled hypertension see them in the office every one to three months, while those from low-cost cities recommended visits twice yearly. In case after uncertain case, more was not necessarily better. But physicians from the most expensive cities did the most expensive things.

Why? Some of it could reflect differences in training. I remember when my wife brought our infant son Walker to visit his grandparents in Virginia, and he took a terrifying fall down a set of stairs. They drove him to the local community hospital in Alexandria. A CT scan showed that he had a tiny subdural hematoma—a small area of bleeding in the brain. During ten hours of observation, though, he was fine—eating, drinking, completely alert. I was a surgery resident then and had seen many cases like his. We observed each child in intensive care for at least twenty-four hours and got a repeat CT scan. That was how I’d been trained. But the doctor in Alexandria was going to send Walker home. That was how he’d been trained. Suppose things change for the worse? I asked him. It’s extremely unlikely, he said, and if anything changed Walker could always be brought back. I bullied the doctor into admitting him anyway. The next day, the scan and the patient were fine. And, looking in the textbooks, I learned that the doctor was right. Walker could have been managed safely either way.

There was no sign, however, that McAllen’s doctors as a group were trained any differently from El Paso’s. One morning, I met with a hospital administrator who had extensive experience managing for-profit hospitals along the border. He offered a different possible explanation: the culture of money.

“In El Paso, if you took a random doctor and looked at his tax returns eighty-five per cent of his income would come from the usual practice of medicine,” he said. But in McAllen, the administrator thought, that percentage would be a lot less.

He knew of doctors who owned strip malls, orange groves, apartment complexes—or imaging centers, surgery centers, or another part of the hospital they directed patients to. They had “entrepreneurial spirit,” he said. They were innovative and aggressive in finding ways to increase revenues from patient care. “There’s no lack of work ethic,” he said. But he had often seen financial considerations drive the decisions doctors made for patients—the tests they ordered, the doctors and hospitals they recommended—and it bothered him. Several doctors who were unhappy about the direction medicine had taken in McAllen told me the same thing. “It’s a machine, my friend,” one surgeon explained.

No one teaches you how to think about money in medical school or residency. Yet, from the moment you start practicing, you must think about it. You must consider what is covered for a patient and what is not. You must pay attention to insurance rejections and government-reimbursement rules. You must think about having enough money for the secretary and the nurse and the rent and the malpractice insurance.

Beyond the basics, however, many physicians are remarkably oblivious to the financial implications of their decisions. They see their patients. They make their recommendations. They send out the bills. And, as long as the numbers come out all right at the end of each month, they put the money out of their minds.

Others think of the money as a means of improving what they do. They think about how to use the insurance money to maybe install electronic health records with colleagues, or provide easier phone and e-mail access, or offer expanded hours. They hire an extra nurse to monitor diabetic patients more closely, and to make sure that patients don’t miss their mammograms and pap smears and colonoscopies.

Then there are the physicians who see their practice primarily as a revenue stream. They instruct their secretary to have patients who call with follow-up questions schedule an appointment, because insurers don’t pay for phone calls, only office visits. They consider providing Botox injections for cash. They take a Doppler ultrasound course, buy a machine, and start doing their patients’ scans themselves, so that the insurance payments go to them rather than to the hospital. They figure out ways to increase their high-margin work and decrease their low-margin work. This is a business, after all.

In every community, you’ll find a mixture of these views among physicians, but one or another tends to predominate. McAllen seems simply to be the community at one extreme.

In a few cases, the hospital executive told me, he’d seen the behavior cross over into what seemed like outright fraud. “I’ve had doctors here come up to me and say, ‘You want me to admit patients to your hospital, you’re going to have to pay me.’ ”

“How much?” I asked.

“The amounts—all of them were over a hundred thousand dollars per year,” he said. The doctors were specific. The most he was asked for was five hundred thousand dollars per year.

He didn’t pay any of them, he said: “I mean, I gotta sleep at night.” And he emphasized that these were just a handful of doctors. But he had never been asked for a kickback before coming to McAllen.

Woody Powell is a Stanford sociologist who studies the economic culture of cities. Recently, he and his research team studied why certain regions—Boston, San Francisco, San Diego—became leaders in biotechnology while others with a similar concentration of scientific and corporate talent—Los Angeles, Philadelphia, New York—did not. The answer they found was what Powell describes as the anchor-tenant theory of economic development. Just as an anchor store will define the character of a mall, anchor tenants in biotechnology, whether it’s a company like Genentech, in South San Francisco, or a university like M.I.T., in Cambridge, define the character of an economic community. They set the norms. The anchor tenants that set norms encouraging the free flow of ideas and collaboration, even with competitors, produced enduringly successful communities, while those that mainly sought to dominate did not.

Powell suspects that anchor tenants play a similarly powerful community role in other areas of economics, too, and health care may be no exception. I spoke to a marketing rep for a McAllen home-health agency who told me of a process uncannily similar to what Powell found in biotech. Her job is to persuade doctors to use her agency rather than others. The competition is fierce. I opened the phone book and found seventeen pages of listings for home-health agencies—two hundred and sixty in all. A patient typically brings in between twelve hundred and fifteen hundred dollars, and double that amount for specialized care. She described how, a decade or so ago, a few early agencies began rewarding doctors who ordered home visits with more than trinkets: they provided tickets to professional sporting events, jewelry, and other gifts. That set the tone. Other agencies jumped in. Some began paying doctors a supplemental salary, as “medical directors,” for steering business in their direction. Doctors came to expect a share of the revenue stream.

Agencies that want to compete on quality struggle to remain in business, the rep said. Doctors have asked her for a medical-director salary of four or five thousand dollars a month in return for sending her business. One asked a colleague of hers for private-school tuition for his child; another wanted sex.

“I explained the rules and regulations and the anti-kickback law, and told them no,” she said of her dealings with such doctors. “Does it hurt my business?” She paused. “I’m O.K. working only with ethical physicians,” she finally said.

About fifteen years ago, it seems, something began to change in McAllen. A few leaders of local institutions took profit growth to be a legitimate ethic in the practice of medicine. Not all the doctors accepted this. But they failed to discourage those who did. So here, along the banks of the Rio Grande, in the Square Dance Capital of the World, a medical community came to treat patients the way subprime-mortgage lenders treated home buyers: as profit centers.

The real puzzle of American health care, I realized on the airplane home, is not why McAllen is different from El Paso. It’s why El Paso isn’t like McAllen. Every incentive in the system is an invitation to go the way McAllen has gone. Yet, across the country, large numbers of communities have managed to control their health costs rather than ratchet them up.

I talked to Denis Cortese, the C.E.O. of the Mayo Clinic, which is among the highest-quality, lowest-cost health-care systems in the country. A couple of years ago, I spent several days there as a visiting surgeon. Among the things that stand out from that visit was how much time the doctors spent with patients. There was no churn—no shuttling patients in and out of rooms while the doctor bounces from one to the other. I accompanied a colleague while he saw patients. Most of the patients, like those in my clinic, required about twenty minutes. But one patient had colon cancer and a number of other complex issues, including heart disease. The physician spent an hour with her, sorting things out. He phoned a cardiologist with a question.

“I’ll be there,” the cardiologist said.

Fifteen minutes later, he was. They mulled over everything together. The cardiologist adjusted a medication, and said that no further testing was needed. He cleared the patient for surgery, and the operating room gave her a slot the next day.

The whole interaction was astonishing to me. Just having the cardiologist pop down to see the patient with the surgeon would be unimaginable at my hospital. The time required wouldn’t pay. The time required just to organize the system wouldn’t pay.

The core tenet of the Mayo Clinic is “The needs of the patient come first”—not the convenience of the doctors, not their revenues. The doctors and nurses, and even the janitors, sat in meetings almost weekly, working on ideas to make the service and the care better, not to get more money out of patients. I asked Cortese how the Mayo Clinic made this possible.

“It’s not easy,” he said. But decades ago Mayo recognized that the first thing it needed to do was eliminate the financial barriers. It pooled all the money the doctors and the hospital system received and began paying everyone a salary, so that the doctors’ goal in patient care couldn’t be increasing their income. Mayo promoted leaders who focussed first on what was best for patients, and then on how to make this financially possible.

No one there actually intends to do fewer expensive scans and procedures than is done elsewhere in the country. The aim is to raise quality and to help doctors and other staff members work as a team. But, almost by happenstance, the result has been lower costs.

“When doctors put their heads together in a room, when they share expertise, you get more thinking and less testing,” Cortese told me.

Skeptics saw the Mayo model as a local phenomenon that wouldn’t carry beyond the hay fields of northern Minnesota. But in 1986 the Mayo Clinic opened a campus in Florida, one of our most expensive states for health care, and, in 1987, another one in Arizona. It was difficult to recruit staff members who would accept a salary and the Mayo’s collaborative way of practicing. Leaders were working against the dominant medical culture and incentives. The expansion sites took at least a decade to get properly established. But eventually they achieved the same high-quality, low-cost results as Rochester. Indeed, Cortese says that the Florida site has become, in some respects, the most efficient one in the system.

The Mayo Clinic is not an aberration. One of the lowest-cost markets in the country is Grand Junction, Colorado, a community of a hundred and twenty thousand that nonetheless has achieved some of Medicare’s highest quality-of-care scores. Michael Pramenko is a family physician and a local medical leader there. Unlike doctors at the Mayo Clinic, he told me, those in Grand Junction get piecework fees from insurers. But years ago the doctors agreed among themselves to a system that paid them a similar fee whether they saw Medicare, Medicaid, or private-insurance patients, so that there would be little incentive to cherry-pick patients. They also agreed, at the behest of the main health plan in town, an H.M.O., to meet regularly on small peer-review committees to go over their patient charts together. They focussed on rooting out problems like poor prevention practices, unnecessary back operations, and unusual hospital-complication rates. Problems went down. Quality went up. Then, in 2004, the doctors’ group and the local H.M.O. jointly created a regional information network—a community-wide electronic-record system that shared office notes, test results, and hospital data for patients across the area. Again, problems went down. Quality went up. And costs ended up lower than just about anywhere else in the United States.

Grand Junction’s medical community was not following anyone else’s recipe. But, like Mayo, it created what Elliott Fisher, of Dartmouth, calls an accountable-care organization. The leading doctors and the hospital system adopted measures to blunt harmful financial incentives, and they took collective responsibility for improving the sum total of patient care.

This approach has been adopted in other places, too: the Geisinger Health System, in Danville, Pennsylvania; the Marshfield Clinic, in Marshfield, Wisconsin; Intermountain Healthcare, in Salt Lake City; Kaiser Permanente, in Northern California. All of them function on similar principles. All are not-for-profit institutions. And all have produced enviably higher quality and lower costs than the average American town enjoys.

When you look across the spectrum from Grand Junction to McAllen—and the almost threefold difference in the costs of care—you come to realize that we are witnessing a battle for the soul of American medicine. Somewhere in the United States at this moment, a patient with chest pain, or a tumor, or a cough is seeing a doctor. And the damning question we have to ask is whether the doctor is set up to meet the needs of the patient, first and foremost, or to maximize revenue.

There is no insurance system that will make the two aims match perfectly. But having a system that does so much to misalign them has proved disastrous. As economists have often pointed out, we pay doctors for quantity, not quality. As they point out less often, we also pay them as individuals, rather than as members of a team working together for their patients. Both practices have made for serious problems.

Providing health care is like building a house. The task requires experts, expensive equipment and materials, and a huge amount of coördination. Imagine that, instead of paying a contractor to pull a team together and keep them on track, you paid an electrician for every outlet he recommends, a plumber for every faucet, and a carpenter for every cabinet. Would you be surprised if you got a house with a thousand outlets, faucets, and cabinets, at three times the cost you expected, and the whole thing fell apart a couple of years later? Getting the country’s best electrician on the job (he trained at Harvard, somebody tells you) isn’t going to solve this problem. Nor will changing the person who writes him the check.

This last point is vital. Activists and policymakers spend an inordinate amount of time arguing about whether the solution to high medical costs is to have government or private insurance companies write the checks. Here’s how this whole debate goes. Advocates of a public option say government financing would save the most money by having leaner administrative costs and forcing doctors and hospitals to take lower payments than they get from private insurance. Opponents say doctors would skimp, quit, or game the system, and make us wait in line for our care; they maintain that private insurers are better at policing doctors. No, the skeptics say: all insurance companies do is reject applicants who need health care and stall on paying their bills. Then we have the economists who say that the people who should pay the doctors are the ones who use them. Have consumers pay with their own dollars, make sure that they have some “skin in the game,” and then they’ll get the care they deserve. These arguments miss the main issue. When it comes to making care better and cheaper, changing who pays the doctor will make no more difference than changing who pays the electrician. The lesson of the high-quality, low-cost communities is that someone has to be accountable for the totality of care. Otherwise, you get a system that has no brakes. You get McAllen.

One afternoon in McAllen, I rode down McColl Road with Lester Dyke, the cardiac surgeon, and we passed a series of office plazas that seemed to be nothing but home-health agencies, imaging centers, and medical-equipment stores.

“Medicine has become a pig trough here,” he muttered.

Dyke is among the few vocal critics of what’s happened in McAllen. “We took a wrong turn when doctors stopped being doctors and became businessmen,” he said.

We began talking about the various proposals being touted in Washington to fix the cost problem. I asked him whether expanding public-insurance programs like Medicare and shrinking the role of insurance companies would do the trick in McAllen.

“I don’t have a problem with it,” he said. “But it won’t make a difference.” In McAllen, government payers already predominate—not many people have jobs with private insurance.

How about doing the opposite and increasing the role of big insurance companies?

“What good would that do?” Dyke asked.

The third class of health-cost proposals, I explained, would push people to use medical savings accounts and hold high-deductible insurance policies: “They’d have more of their own money on the line, and that’d drive them to bargain with you and other surgeons, right?”

He gave me a quizzical look. We tried to imagine the scenario. A cardiologist tells an elderly woman that she needs bypass surgery and has Dr. Dyke see her. They discuss the blockages in her heart, the operation, the risks. And now they’re supposed to haggle over the price as if he were selling a rug in a souk? “I’ll do three vessels for thirty thousand, but if you take four I’ll throw in an extra night in the I.C.U.”—that sort of thing? Dyke shook his head. “Who comes up with this stuff?” he asked. “Any plan that relies on the sheep to negotiate with the wolves is doomed to failure.”

Instead, McAllen and other cities like it have to be weaned away from their untenably fragmented, quantity-driven systems of health care, step by step. And that will mean rewarding doctors and hospitals if they band together to form Grand Junction-like accountable-care organizations, in which doctors collaborate to increase prevention and the quality of care, while discouraging overtreatment, undertreatment, and sheer profiteering. Under one approach, insurers—whether public or private—would allow clinicians who formed such organizations and met quality goals to keep half the savings they generate. Government could also shift regulatory burdens, and even malpractice liability, from the doctors to the organization. Other, sterner, approaches would penalize those who don’t form these organizations.

This will by necessity be an experiment. We will need to do in-depth research on what makes the best systems successful—the peer-review committees? recruiting more primary-care doctors and nurses? putting doctors on salary?—and disseminate what we learn. Congress has provided vital funding for research that compares the effectiveness of different treatments, and this should help reduce uncertainty about which treatments are best. But we also need to fund research that compares the effectiveness of different systems of care—to reduce our uncertainty about which systems work best for communities. These are empirical, not ideological, questions. And we would do well to form a national institute for health-care delivery, bringing together clinicians, hospitals, insurers, employers, and citizens to assess, regularly, the quality and the cost of our care, review the strategies that produce good results, and make clear recommendations for local systems.

Dramatic improvements and savings will take at least a decade. But a choice must be made. Whom do we want in charge of managing the full complexity of medical care? We can turn to insurers (whether public or private), which have proved repeatedly that they can’t do it. Or we can turn to the local medical communities, which have proved that they can. But we have to choose someone—because, in much of the country, no one is in charge. And the result is the most wasteful and the least sustainable health-care system in the world.

Something even more worrisome is going on as well. In the war over the culture of medicine—the war over whether our country’s anchor model will be Mayo or McAllen—the Mayo model is losing. In the sharpest economic downturn that our health system has faced in half a century, many people in medicine don’t see why they should do the hard work of organizing themselves in ways that reduce waste and improve quality if it means sacrificing revenue.

In El Paso, the for-profit health-care executive told me, a few leading physicians recently followed McAllen’s lead and opened their own centers for surgery and imaging. When I was in Tulsa a few months ago, a fellow-surgeon explained how he had made up for lost revenue by shifting his operations for well-insured patients to a specialty hospital that he partially owned while keeping his poor and uninsured patients at a nonprofit hospital in town. Even in Grand Junction, Michael Pramenko told me, “some of the doctors are beginning to complain about ‘leaving money on the table.’ ”

As America struggles to extend health-care coverage while curbing health-care costs, we face a decision that is more important than whether we have a public-insurance option, more important than whether we will have a single-payer system in the long run or a mixture of public and private insurance, as we do now. The decision is whether we are going to reward the leaders who are trying to build a new generation of Mayos and Grand Junctions. If we don’t, McAllen won’t be an outlier. It will be our future.